GJB1 and multiple sclerosis: In agreement with the previous findings, a 22-year-old patient manifesting with CNS involvement, harboring substitution of Ser26Leu in Cx32, showed a positive response to the treatment with methylprednisolone and natalizumab (a glucocorticosteroid with anti-inflammatory and immunosuppressive effects and monoclonal antibody, respectively), normally used in the treatment of the patients with multiple sclerosis [17].